The Reemergence of Psychedelics: Implications for Behavioral Health Treatment

The field of psychedelic medicine has gained significant popularity over the past two to three years, with attention focused on uses for behavioral health disorders and even well-being.

Watch this on-demand session to review the use of psychedelic substances and how they impact the brain and behavior. Specifically, this webinar discusses psilocybin (a.k.a. “magic mushrooms”), MDMA, and ketamine, as new research shows positive impacts on various mental health and substance use disorders.

Additionally, we discuss current regulatory issues and challenges from the perspective of what this means for practicing clinicians. Since we expect the therapeutic psychedelics industry to grow from $3.6 billion in 2021 to $8.3 billion in 2028, will psychedelics become mainstream in behavioral health?

By attending, you’ll learn the following:

• How psychedelics impact the brain and behavior
• Which behavioral health disorders have shown positive treatment results from psychedelics
• The regulatory status of specific psychedelics and how this may affect some future treatment interventions